{"id":18409,"date":"2026-08-21T08:29:50","date_gmt":"2026-08-21T11:29:50","guid":{"rendered":"https:\/\/www.biolabeco.com.br\/?post_type=imprensa&#038;p=18409"},"modified":"2026-08-21T08:31:54","modified_gmt":"2026-08-21T11:31:54","slug":"biolab-co-and-sandoz-announce-the-launch-of-owozy-semaglutide-in-the-brazilian-market","status":"publish","type":"imprensa","link":"https:\/\/www.biolabeco.com.br\/en\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/","title":{"rendered":"Biolab &amp; Co. and Sandoz Announce the Launch of Owozy (semaglutide) in the Brazilian Market"},"content":{"rendered":"<ul>\n<li><em>The partnership combines Biolab &amp; Co.'s national presence with Sandoz's global expertise to expand access to the medication and support its distribution in the country<\/em><\/li>\n\n\n\n<li><em>The goal is to place physicians at the center of the expansion strategy for GLP-1 medications, prioritizing responsible prescribing and access to innovation<\/em><\/li>\n<\/ul>\n\n\n\n<p><strong>S\u00e3o Paulo, <\/strong><strong>August 19, 2026 \u2013 <\/strong>The launch of Owozy (semaglutide) in the Brazilian market is supported by a partnership that combines Biolab &amp; Co.\u2019s national presence with Sandoz\u2019s global expertise. The medication remains stable for up to 42 days at temperatures of up to 30\u00b0C, a feature that allows for greater flexibility in storage during the period of use.<\/p>\n\n\n\n<p>Under the agreement, announced on Wednesday (19), Biolab Farmac\u00eautica will be responsible for the medical promotion and marketing strategy for the drug, while Sandoz will be responsible for supplying the product. The partnership aims to make access to type 2 diabetes treatment more widely available and to raise awareness about the care and treatment of the disease. The move solidifies Biolab\u2019s leadership in the cardiometabolic health segment.<\/p>\n\n\n\n<p>The drug is expected to reach the market in the fourth quarter of 2026, backed by an extensive promotional campaign targeting the medical community.<\/p>\n\n\n\n<p><em>\u201cOwozy\u2019s entry into the Brazilian market represents an important opportunity to expand access to a high-quality treatment option for type 2 diabetes. <\/em><em>\u201dTogether with Biolab &amp; Co., we are reinforcing our commitment to connecting more patients with reliable and affordable medicines through partnerships that combine innovation, market knowledge, and local execution capabilities,\",<\/em> says Isabella Wanderley, president of Sandoz Brazil.<\/p>\n\n\n\n<p>Owozy is the result of a global development platform led by Adalvo, with \u00c1vita Care serving as the local regulatory representative during the approval process with Anvisa. The drug\u2019s development was guided by rigorous regulatory requirements and by standards of quality, safety, and efficacy consistent with the level of trust expected of an approved therapeutic option for the treatment of type 2 diabetes.<\/p>\n\n\n\n<p><em>\u201c<\/em><em>GLP-1 medications are currently experiencing rapid growth, and our role, as a leader in cardiology, is to ensure that this innovation reaches patients responsibly and under medical supervision. \u201dOur partnership with Sandoz to market Owozy builds on our strong track record of supporting the medical community across various specialties, leveraging the strength of our sales force to expand safe access to this therapy in Brazil.\u201d<\/em><em>, <\/em>says Fabio Amorosino, president of Biolab &amp; Co.<\/p>\n\n\n\n<p>Biolab Farmac\u00eautica is part of Biolab &amp; Co., a Brazilian pharmaceutical group that comprises six brands and has a portfolio of more than 900 products in the human health, veterinary health, and animal nutrition segments.<\/p>\n\n\n\n<p><strong>ABOUT THE MEDICATION<\/strong><\/p>\n\n\n\n<p>Owozy will be available in Brazil in <strong>Pre-filled delivery system (multidose and disposable pens)<\/strong>, designed to make it easier for patients and healthcare professionals to manage type 2 diabetes. The product should be stored according to the instructions in the package insert. When refrigerated, the pen can be stored for up to 24 months, and after removal from the refrigerator, it can remain at room temperature for up to 42 days.\u00b9<\/p>\n\n\n\n<p>The approved presentations include:<\/p>\n\n\n\n<ul>\n<li><strong>Semaglutide 1.34 mg\/mL injectable solution<\/strong>, in an application form filled out with <strong>1.5 mL<\/strong>, accompanied by <strong>1 pen and 6 needles<\/strong><\/li>\n\n\n\n<li><strong>Semaglutide 1.34 mg\/mL injectable solution<\/strong>, in an application form filled out with <strong>3.0 mL<\/strong>, accompanied by <strong>1 pen and 4 needles<\/strong><\/li>\n<\/ul>\n\n\n\n<p>This medication is indicated for <strong>weekly administration<\/strong>, as directed by a doctor.<\/p>\n\n\n\n<p>The presentations adhere to technical criteria and international development standards, with a focus on <strong>consistency of treatment, safety in use, and suitability for the needs of patients with type 2 diabetes.<\/strong><\/p>\n\n\n\n<p><strong>REFERENCES<\/strong><\/p>\n\n\n\n<ol>\n<li>Official Gazette of the United States. Resolution-Re No.\u00a0<a href=\"https:\/\/www.in.gov.br\/web\/dou\/-\/resolucao-re-n-2.942-de-28-de-julho-de-2026-722060184\" target=\"_blank\" rel=\"noreferrer noopener\">2.942\/2026.<\/a>\u00a0Available at:\u00a0<a href=\"https:\/\/www.in.gov.br\/web\/dou\/-\/resolucao-re-n-2.942-de-28-de-julho-de-2026-722060184\" target=\"_blank\" rel=\"noreferrer noopener\">RESOLUTION-RE No. 2,942, OF JULY 28, 2026 \u2013 RESOLUTION-RE No. 2,942, OF JULY 28, 2026 \u2013 DOU \u2013 National Press<\/a>. Accessed on: July 29, 2026.<\/li>\n<\/ol>\n\n\n\n<p><strong>About Biolab&amp;Co<\/strong><\/p>\n\n\n\n<p>Biolab &amp; Co. is a brand that combines science, innovation, and health, operating in the fields of human health, veterinary medicine, and animal nutrition. Driven by knowledge and collaboration, the company\u2019s mission is to develop and offer therapeutic solutions that have a positive impact on society, always guided by ethics, purpose, and integrity.<\/p>\n\n\n\n<p>The group comprises six brands and a portfolio of more than 900 products. Its structure consists of the following business units: Biolab Farmac\u00eautica, Biolab Gen\u00e9ricos, Avert Sa\u00fade Humana, Avert Biolab Sa\u00fade Animal, Exzell Pharma, and Pet Nutrition.<\/p>\n\n\n\n<p>With the vision of becoming the leading Brazilian pharmaceutical group in its markets, Biolab &amp; Co. operates three production facilities in the state of S\u00e3o Paulo and one in Minas Gerais, in addition to two Research, Development, and Innovation (R&amp;D&amp;I) centers. The group is also expanding its reach through its operation in Canada, where it markets products and maintains its own R&amp;D&amp;I center\u2014the only one outside Brazil operated by a Brazilian pharmaceutical company. The result of this investment is more than 50 international partnerships and a track record of over 400 patent applications, reflecting a culture of continuous improvement and a focus on excellence. Currently, more than 50% of its revenue comes from innovative and exclusive products.<\/p>\n\n\n\n<p><\/p>","protected":false},"featured_media":18411,"template":"","categories":[1576],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.4 (Yoast SEO v24.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biolab &amp; Co. e Sandoz anunciam chegada de Owozy (semaglutida) ao mercado brasileiro - Biolab &amp; Co<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biolabeco.com.br\/en\/press\/biolab-co-and-sandoz-announce-the-launch-of-owozy-semaglutide-in-the-brazilian-market\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biolab &amp; Co. e Sandoz anunciam chegada de Owozy (semaglutida) ao mercado brasileiro\" \/>\n<meta property=\"og:description\" content=\"S\u00e3o Paulo, 19 de agosto de 2026 \u2013 A chegada de Owozy (semaglutida) ao mercado brasileiro \u00e9 apoiada por uma parceria que une a presen\u00e7a nacional da Biolab &amp; Co. \u00e0 experi\u00eancia global da Sandoz. O medicamento conta com estabilidade durante o uso por at\u00e9 42 dias em temperatura de at\u00e9 30\u00baC, caracter\u00edstica que contribui [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biolabeco.com.br\/en\/press\/biolab-co-and-sandoz-announce-the-launch-of-owozy-semaglutide-in-the-brazilian-market\/\" \/>\n<meta property=\"og:site_name\" content=\"Biolab &amp; Co\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-21T11:31:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/08\/Sandoz-e-Biolab_assinatura-acordo-8473-2-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1761\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/\",\"url\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/\",\"name\":\"Biolab &amp; Co. e Sandoz anunciam chegada de Owozy (semaglutida) ao mercado brasileiro - Biolab &amp; Co\",\"isPartOf\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/08\/Sandoz-e-Biolab_assinatura-acordo-8473-2-scaled.jpg\",\"datePublished\":\"2026-08-21T11:29:50+00:00\",\"dateModified\":\"2026-08-21T11:31:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/#primaryimage\",\"url\":\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/08\/Sandoz-e-Biolab_assinatura-acordo-8473-2-scaled.jpg\",\"contentUrl\":\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/08\/Sandoz-e-Biolab_assinatura-acordo-8473-2-scaled.jpg\",\"width\":2560,\"height\":1761},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biolabeco.com.br\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biolab &amp; Co. e Sandoz anunciam chegada de Owozy (semaglutida) ao mercado brasileiro\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biolabeco.com.br\/#website\",\"url\":\"https:\/\/www.biolabeco.com.br\/\",\"name\":\"Biolab\",\"description\":\"Na Biolab &amp; Co, ci\u00eancia e cuidado caminham juntos. Saiba como promovemos sa\u00fade com responsabilidade socioambiental e tecnologia.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biolabeco.com.br\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biolab &amp; Co. and Sandoz Announce the Launch of Owozy (semaglutide) in the Brazilian Market - Biolab &amp; Co.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biolabeco.com.br\/en\/press\/biolab-co-and-sandoz-announce-the-launch-of-owozy-semaglutide-in-the-brazilian-market\/","og_locale":"en_US","og_type":"article","og_title":"Biolab &amp; Co. e Sandoz anunciam chegada de Owozy (semaglutida) ao mercado brasileiro","og_description":"S\u00e3o Paulo, 19 de agosto de 2026 \u2013 A chegada de Owozy (semaglutida) ao mercado brasileiro \u00e9 apoiada por uma parceria que une a presen\u00e7a nacional da Biolab &amp; Co. \u00e0 experi\u00eancia global da Sandoz. O medicamento conta com estabilidade durante o uso por at\u00e9 42 dias em temperatura de at\u00e9 30\u00baC, caracter\u00edstica que contribui [&hellip;]","og_url":"https:\/\/www.biolabeco.com.br\/en\/press\/biolab-co-and-sandoz-announce-the-launch-of-owozy-semaglutide-in-the-brazilian-market\/","og_site_name":"Biolab &amp; Co","article_modified_time":"2026-08-21T11:31:54+00:00","og_image":[{"width":2560,"height":1761,"url":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/08\/Sandoz-e-Biolab_assinatura-acordo-8473-2-scaled.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/","url":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/","name":"Biolab &amp; Co. and Sandoz Announce the Launch of Owozy (semaglutide) in the Brazilian Market - Biolab &amp; Co.","isPartOf":{"@id":"https:\/\/www.biolabeco.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/#primaryimage"},"image":{"@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/08\/Sandoz-e-Biolab_assinatura-acordo-8473-2-scaled.jpg","datePublished":"2026-08-21T11:29:50+00:00","dateModified":"2026-08-21T11:31:54+00:00","breadcrumb":{"@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/#primaryimage","url":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/08\/Sandoz-e-Biolab_assinatura-acordo-8473-2-scaled.jpg","contentUrl":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/08\/Sandoz-e-Biolab_assinatura-acordo-8473-2-scaled.jpg","width":2560,"height":1761},{"@type":"BreadcrumbList","@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-sandoz-anunciam-chegada-de-owozy-semaglutida-ao-mercado-brasileiro\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biolabeco.com.br\/"},{"@type":"ListItem","position":2,"name":"Biolab &amp; Co. e Sandoz anunciam chegada de Owozy (semaglutida) ao mercado brasileiro"}]},{"@type":"WebSite","@id":"https:\/\/www.biolabeco.com.br\/#website","url":"https:\/\/www.biolabeco.com.br\/","name":"Biolab","description":"At Biolab &amp; Co, science and care go hand in hand. Find out how we promote health with social and environmental responsibility and technology.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biolabeco.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/imprensa\/18409"}],"collection":[{"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/imprensa"}],"about":[{"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/types\/imprensa"}],"version-history":[{"count":1,"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/imprensa\/18409\/revisions"}],"predecessor-version":[{"id":18412,"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/imprensa\/18409\/revisions\/18412"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/media\/18411"}],"wp:attachment":[{"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/media?parent=18409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biolabeco.com.br\/en\/wp-json\/wp\/v2\/categories?post=18409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}